๐”– Scriptorium
โœฆ   LIBER   โœฆ
๐Ÿ“

Antiplatelet and Anticoagulation Therapy

โœ Scribed by Stan Heptinstall B.Sc., Ph.D. (auth.), Albert Ferro, David A. Garcia (eds.)

Publisher
Springer-Verlag London
Year
2013
Tongue
English
Leaves
255
Series
Current Cardiovascular Therapy
Edition
1
Category
Library
โฌ‡  Acquire This Volume

No coin nor oath required. For personal study only.

โœฆ Synopsis

This title will be presented as highly practical information pn pharmaceutical antiplatelet and anticoagulation therapy, written in a quick-access, no-nonsense format. The emphasis will be on a just-the-facts clinical approach, heavy on tabular material, light on dense prose. The involvement of the ISCP will ensure that the best quality contributors will be involved and establish a consistent approach to each topic in the series. Each volume is designed to be between 120 and 250 pages containing practical illustrations and designed to improve understand and practical usage of cardiovascular drugs in specific clinical areas.

โœฆ Table of Contents

Front Matter....Pages i-x
Antiplatelet Agents: Current and Novel....Pages 1-44
Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring....Pages 45-112
Anticoagulant Drugs: Current and Novel....Pages 113-141
Antithrombotic Treatment of Cardiovascular Disease....Pages 143-173
Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease....Pages 175-237
Back Matter....Pages 239-247

โœฆ Subjects

Cardiology; Medicine/Public Health, general

๐Ÿ“œ SIMILAR VOLUMES

Anticoagulants, Antiplatelets, and Throm
๐Ÿ“ Anticoagulants, Antiplatelets, and Thrombolytics
โœ Shaker A. Mousa (auth.), Shaker A. Mousa (eds.) ๐Ÿ“‚ Library ๐Ÿ“… 2004 ๐Ÿ› Springer New York ๐ŸŒ English

During the past decade, remarkable progress has been made in the development of new drugs to treat thrombotic and cardiovascular diseases, the number one cause of mortality worldwide. In Anticoagulants, Antiplatelets, and Thrombolytics, leading experts with established records of discovery and inven

Anticoagulants, Antiplatelets, and Throm
๐Ÿ“ Anticoagulants, Antiplatelets, and Thrombolytics
โœ Shaker A. Mousa ๐Ÿ“‚ Library ๐Ÿ“… 2010 ๐Ÿ› Humana Press ๐ŸŒ English

This practical collection provides a comprehensive update on clinically relevant in vitro and in vivo models of thrombosis and hemostasis for the discovery and testing of antithrombotics, and summarizes recent development in pharmaceuticals for the prevention and treatment of various thromboembolic

Anticoagulants, Antiplatelets, and Throm
๐Ÿ“ Anticoagulants, Antiplatelets, and Thrombolytics: Second Edition
โœ Shaker A. Mousa (auth.), Shaker A. Mousa (eds.) ๐Ÿ“‚ Library ๐Ÿ“… 2010 ๐Ÿ› Humana Press ๐ŸŒ English

<p>During the past decade, remarkable progress has been made in the development of newer drugs to prevent and treat thromboembolic disorders, such as oral direct anti-Xa and anti-IIa antagonists, as well as oral antiplatelet ADP antagonists with rapid onset and offset. In addition, there has been co

Anticoagulants, Antiplatelets, and Throm
๐Ÿ“ Anticoagulants, Antiplatelets, and Thrombolytics (Methods in Molecular Medicine)
โœ Shaker A. Mousa ๐Ÿ“‚ Library ๐Ÿ“… 2003 ๐ŸŒ English

1This collection of review articles highlights the latest development of antithrombotics and provides proven experimental methods for the further development of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such an